WW CEO pivots strategy amid rise of GLP-1 drugs, FT reports

WeightWatchers CEO Tara Comonte is pivoting amid the rise of GLP-1 drugs after the company’s subscriber base fell 30% from its peak in 2018, the Financial Times’ Brooke Masters reports, citing company executives. The CEO has recruited new leadership, doubled down on the company’s 2023 purchase of a telehealth group that enabled it to enter the diet drug space and plans to unveil a menopause care option in the fall. “We help members manage side effects, adjust their nutrition and talk about what it means to show up in a new body or how to get through the holidays without drinking or eating so much,” said Kim Boyde. “That community component is enormously important, especially in this day and age when we are more disconnected and lonely.”